Antibodies relating to PIVKAII and uses thereof

• US 8,283,162 B2
• Filed: 03/10/2009
• Issued: 10/09/2012
• Est. Priority Date: 03/10/2009
• Status: Active Grant

• Current Assignee: Abbott Japan LLC (Abbott Laboratories Incorporated)
• Original Assignee: Abbott Laboratories Incorporated
• Inventors: Yoshimura, Toru, Dowell, Barry L., Beligere, Gangamani S., Ruan, Qiaoqiao
• Primary Examiner(s): AEDER, SEAN E
• Application Number:
  US12/401,361
• Publication Number:
  US 20100233175A1
• Time in Patent Office: 1,309 Days
• Field of Search: None
• US Class Current: 435/326
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07K 16/40 against enzymes
• CPC Class Codes: C07K 2317/92 Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
• CPC Class Codes: G01N 33/57438 of liver, pancreas or kidney

Abstract

The present invention relates to antibodies that may be used, for example, in the diagnosis, treatment and prevention of haepatocellular carcinoma (HCC), liver cancer and related conditions.

Claims

1. A hybridoma cell line designated by American Type Culture Collection (ATCC) deposit designation PTA-9638.

2. The monoclonal antibody produced by said hybridoma cell line of claim 1.

3. An isolated nucleic acid molecule fully encoding a binding protein which binds to PIVKA-II, wherein said binding protein comprises a variable heavy chain of said monoclonal antibody of claim 2.

4. The isolated nucleic acid molecule of claim 3, wherein said binding protein binds to amino acids 13-27 of PIVKA-II.

5. A purified protein fully encoded by said isolated nucleic acid molecule of claim 3, wherein said purified protein binds to PIVKA-II.

6. A vector comprising said isolated nucleic acid molecule of claim 3.

7. An isolated host cell comprising said vector of claim 6.

9. A pharmaceutical composition comprising the monoclonal antibody of claim 2 and a pharmaceutically acceptable carrier.

10. A kit comprising a container containing said monoclonal antibody of claim 2.

8. A method of producing a hybridoma cell line which expresses a binding protein comprising an antigen-binding domain which binds to amino acids 13-27 of PIVKA-II comprising the steps of:

a) immunizing a GANP mouse with an antigen comprising amino acids 13-27 of PIVKA-II for a time and under conditions sufficient for said mouse to produce antibodies against said antigen;

b) harvesting and purifying B cells from the spleen of said mouse;

c) fusing said spleen cells with myeloma cells in order to produce hybridomas; and

d) selecting a hybridoma cell line which expresses said binding protein comprising an antigen-binding domain which binds to amino acids 13-27 of PIVKA-II, wherein said hybridoma cell line has ATCC deposit designation PTA-9638.